Yüklüyor......
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
BACKGROUND: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab....
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ https://ncbi.nlm.nih.gov/pubmed/21991949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0910383 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|